^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Title:

ST6GAL1 is a novel serum biomarker for lenvatinib-susceptible FGF19-driven hepatocellular carcinoma

Published date:
12/07/2020
Excerpt:
...lenvatinib and sorafenib, are used as standard-of-care chemotherapeutics in advanced HCC patients...sorafenib eliminated MET- and NRAS-expressing tumors.
DOI:
10.1158/1078-0432.CCR-20-3382